Corneal edema
diseaseOn this page
Summary
Corneal edema (MONDO:0006712) is a disease with 4 GWAS associations across 4 studies and 33 clinical trials. Top therapeutic interventions include prednisolone, timolol, and loteprednol etabonate. A subtype of corneal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 4
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | corneal edema |
| Mondo ID | MONDO:0006712 |
| EFO | EFO:1000879 |
| MeSH | D015715 |
| DOID | DOID:11030 |
| SNOMED CT | 27194006 |
| UMLS | C0010037 |
| MedGen | 3242 |
| MedDRA | 10011007 |
| Is cancer (heuristic) | no |
Data availability: 4 GWAS associations (4 studies).
Disease family
This is a subtype of corneal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › corneal disorder › corneal edema
Related subtypes (23): cornea plana, pseudopterygium, corneal deposit, Bowman’s membrane folds or rupture, corneal degeneration, corneal staphyloma, corneal argyrosis, corneal ectasia, keratopathy, keratitis, brittle cornea syndrome, megalocornea, X-linked corneal dermoid, Peters anomaly, pellucid marginal degeneration, keratoconus, corneal dystrophy, sclerocornea, cornea neoplasm, Arnold stickler bourne syndrome, limbal stem cell deficiency, thygeson superficial punctate keratopathy, Terrien marginal degeneration
Subtypes (4): bullous keratopathy, secondary corneal edema, idiopathic corneal edema, contact lens corneal edema
Genetics & variants
GWAS landscape
4 GWAS associations across 4 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs11659764 | 1e-59 | TCF4 - LINC01415 | T | 0.93 |
| rs547930665 | 3e-12 | ARHGAP21 - PRTFDC1 | C | 2.69 |
| rs183734012 | 8e-12 | LINC01919 - MBD2 | T | 1.51 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90475862 | Verma A | 2024 | 1,822 | 447,660 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480059 | Verma A | 2024 | 459 | 121,058 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481909 | Verma A | 2024 | 459 | 121,058 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435977 | Zhou W | 2018 | 80 | 397,761 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 3 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 1 |
| rare (<0.01) | 2 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 2 |
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs11659764 | 18 | 55668281 | T>A,G | 0.038 | intron_variant | TCF4 - LINC01415 | 1e-59 | Tier 4: intronic/intergenic |
| rs547930665 | 10 | 24740238 | C>G | 0.001 | intergenic_variant | ARHGAP21 - PRTFDC1 | 3e-12 | Tier 4: intronic/intergenic |
| rs183734012 | 18 | 53845739 | T>A,C,G | 0.002 | intergenic_variant | LINC01919 - MBD2 | 8e-12 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Sodium Chloride | Approved (phase 4) |
| Dexamethasone | Phase 3 (in late-stage trials) |
| Ripasudil | Phase 3 (in late-stage trials) |
| Triamcinolone | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Netarsudil.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 16 |
| PHASE4 | 6 |
| PHASE1 | 5 |
| PHASE3 | 3 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01244334 | PHASE4 | COMPLETED | Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. |
| NCT01387620 | PHASE4 | COMPLETED | Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2% |
| NCT01853696 | PHASE4 | COMPLETED | Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty |
| NCT04521140 | PHASE4 | COMPLETED | Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery |
| NCT05136443 | PHASE4 | COMPLETED | Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection |
| NCT05626478 | PHASE4 | COMPLETED | Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery |
| NCT07368959 | PHASE3 | RECRUITING | AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction |
| NCT00800423 | PHASE3 | UNKNOWN | Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema |
| NCT05271058 | PHASE3 | COMPLETED | Effect of Intracameral Steroids During Phacoemulsification on the Cornea |
| NCT06630169 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Cryopreserved AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction |
| NCT04498169 | PHASE2 | COMPLETED | A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy |
| NCT06041256 | PHASE1/PHASE2 | COMPLETED | A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) |
| NCT05636579 | PHASE1 | RECRUITING | Study to Assess Safety and Tolerability of Multiple Doses of EO2002 |
| NCT07325097 | PHASE1 | RECRUITING | PVEK Corneal Implant For Treatment of Corneal Edema |
| NCT04191629 | PHASE1 | UNKNOWN | Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema |
| NCT04894110 | PHASE1 | COMPLETED | Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema |
| NCT05309135 | PHASE1 | COMPLETED | A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction |
| NCT05436665 | Not specified | RECRUITING | The Belgian Endothelial Surgical Transplant of the Cornea |
| NCT06261346 | Not specified | RECRUITING | Plasma Rich in Growth Factors in Corneal Endothelial Transplantation |
| NCT06983652 | Not specified | RECRUITING | Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema |
| NCT07344168 | Not specified | NOT_YET_RECRUITING | EndoArt® Implantation in Subjects With Chronic Corneal Edema - US Study |
| NCT00346138 | Not specified | COMPLETED | A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema |
| NCT00624221 | Not specified | COMPLETED | Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty |
| NCT01890252 | Not specified | COMPLETED | Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema |
| NCT01998568 | Not specified | COMPLETED | The Intraocular Pressure Measured by Different Tonometers in Corneal Edema |
| NCT02332109 | Not specified | COMPLETED | ODM 5 in the Treatment of Corneal Edematous Fuchs’ Endothelial Dystrophy |
| NCT02660151 | Not specified | COMPLETED | Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema |
| NCT04125394 | Not specified | UNKNOWN | Efficacy and Tolerance of Hypertonic Sodium Chloride (NaCl 5%) Eye Drops Without Preservatives in Corneal Edema |
| NCT04975971 | Not specified | COMPLETED | A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery |
| NCT05139771 | Not specified | COMPLETED | EndoArt® Implantation in Subjects With Chronic Corneal Edema |
| NCT05891106 | Not specified | COMPLETED | AONDA Therapeutic Indication Study I |
| NCT05956535 | Not specified | COMPLETED | Air Optix® Night and Day® Aqua Therapeutic Wear |
| NCT07605273 | Not specified | COMPLETED | Comparison of 5% Hypertonic Saline Versus 3% Hypertonic Saline in Resolution of Post-operative Corneal Edema. |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PREDNISOLONE | 4 | 4 |
| TIMOLOL | 4 | 3 |
| LOTEPREDNOL ETABONATE | 4 | 2 |
| BRIMONIDINE TARTRATE | 4 | 1 |
| BROMFENAC SODIUM | 4 | 1 |
| HYALURONIC ACID | 4 | 1 |
| HYPROMELLOSE | 4 | 1 |
| NETARSUDIL | 4 | 1 |
| RIPASUDIL | 3 | 2 |
| CHEMBL1994526 | 0 | 1 |
| Y-27632 | 0 | 1 |